Peptonic växer kraftigt i Q3 med 68 procent och visar på en tydlig resultatförbättring.
Redeye concludes that Q4 was more or less exactly in line with Redeye’s sales estimates – both for A...
Redeye provides a research update following Penneo’s updated 2022 EBITDA guidance, while preliminary...
Redeye comments on the new positive phase I data from the Lipisense trial.
Israeli-based mobile gaming company Playtika has today announced a proposal to Rovio board of direct...
Prelim. ARR of DKK 71m corresponds to 28% y-o-y growth New '22 adj.
Redeye sees the FDA's fast track designation for EVX-01 as a validation of the personalised vaccin a...
Redeye comments on Isofol’s board proposing a liquidation of the company after considering different...
Redeye comments on CLS’ announcement that the company repays SEK3m of its loan with a directed share...
Targets SEK 2bn in revenue and adj. EBITA margin 6% in 2023 Targets 10% org.
Redeye lowers its valuation of Irlab following yesterday’s phase IIb top-line data with Mesdopetam i...
Q4 report due 21 February We forecast sales of SEK 190m, adj.
Redeye provides a research update following Xavi Solutions’ updated financial targets.
Redeye updates its estimates ahead of the Q4 report (due 22 February) with slight downward adjustmen...
IRLAB Therapeutics has announced top-line data from its Phase IIb trial investigating mesdopetam as ...
Redeye leaves its view on Idogen following the outcome of its rights issue.
Trots stark försäljning var Q3 ett svalt kvartal utan nya ordar.
EcoRub tillkännagav den 17 januari att bolaget startat ett samarbete med Svensk Däckåtervinning för ...
IRLAB fails primary endpoint in PD-LIDs Positive secondary endpoint keeps the door open Conference c...
NoHo Partners has been selected as the main supplier for restaurant services by Helsinki Expo and Co...
